European Perspectives on Key Studies Influencing HIV Care Following IAS 2019

European Perspectives on Key Studies Influencing HIV Care Following IAS 2019 (July 2019)

Friday, July 26, 2019
Webinar -- 1:00 PM ET

Agenda

Program Overview (5 mins)

Updating My Practice Following IAS 2019 (25 mins)

  • Summary of the most important studies
  • Key practice recommendations for the clinic

Question and Answer Session (15 mins)

Faculty

Faculty
J├╝rgen K. Rockstroh, MD

Professor of Medicine
University of Bonn
Bonn, Germany

Program Overview
You are invited to attend a CME/CE-certified Webinar highlighting key take-home messages from the 10th IAS Conference on HIV Science.

Goal Statement
The goal of this activity is to improve participants’ competence in translating the most clinically significant data from IAS 2019 into practical management strategies for individuals at risk of or infected with HIV.

Target Audience 
This program is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with HIV.

Learning Objectives

  • Apply data from studies of ARV agents used to prevent HIV infection
  • Devise management strategies based on the results of recent clinical studies of established ARV agents in patients living with HIV
  • Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens

Accreditation

Joint Accreditation Statement

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Education

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.75 contact hour may be earned by learners who successfully complete this continuing nursing education activity.

Pharmacist Continuing Education


USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.75 contact hour (0.075 CEU). Universal program number is as follows: (0230-9999-19-015-L02-P).

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@health.usf.edu.

Disclosure of Conflicts of Interest 
USF Health adheres to ACCME, ANCC, and ACPE Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

USF Health Office of Continuing Professional Development staff has nothing to disclose.

The planners/managers reported the following relationships:

Megan K. Murphy, PhD; Jennifer M. Blanchette, PhD; Edward King, MA; Kiran D. Mir-Hudgeons, PhD; Tiffany Hensley-McBain, PhD; Megan Cartwright, PhD; Julie Skowronski, FNP-BC; and Anna Poppa have no relevant conflicts of interest to report.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Carlos del Rio, MD, has no relevant conflicts of interest to report.

Jean-Michel Molina, MD, PhD, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and funds for research support paid to his institution from Gilead Sciences.

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for non-CME/CE services from Gilead Sciences, Janssen, Merck, and ViiV Healthcare.

Paul E. Sax, MD, has disclosed that he has received consulting fees from Gilead Sciences, GSK, Janssen, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences, GSK, Merck, and ViiV Healthcare.

The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

If you have any questions relating to the continuing education accreditation of this activity, please contact USF Health at 813-224-7860 or cpdsupport@health.usf.edu.